The Role of Clinical Research Professionals: From Early Discovery to Phase III Success

Clinical research professionals are often measured by the milestones they achieve; first patient enrolled, database lock, regulatory approval. Yet some of the most valuable contributions occur when development programs encounter setbacks. The ability to analyze failure, adapt strategy, and rebuild momentum has become just as important as operational excellence in bringing innovative therapies to patients.

As clinical development has evolved to encompass advanced therapies such as cell and gene therapies, the role of clinical research professionals has expanded significantly. Early-stage programs frequently require close collaboration between sponsors and regulators as novel technologies move from discovery into first-in-human studies. Transparent communication, thoughtful risk management, and a willingness to adapt as evidence emerges are essential for navigating the uncertainty that accompanies scientific innovation.

These qualities become even more important during late-stage development, where the stakes are considerably higher. Large global Phase III trial programs involve years of planning, hundreds of investigators, and thousands of patients. When such a study fails to achieve its primary endpoint, the impact extends beyond data, affecting teams that have invested years of scientific expertise and operational commitment. While many clinical trials end at this stage, failure can also become the foundation for future success when organizations are willing to interrogate the evidence rather than abandon it.

One experience that fundamentally shaped my perspective on the value of adaptive clinical development came through the evolution of a novel therapy designed to address a significant unmet need in surgical infection prevention. Despite years of planning, execution, and investment, the first pivotal study, conducted during the COVID-19 pandemic did not meet its primary endpoint, a result that could easily have marked the end of the trial.

Based on learnings from the study, the multidisciplinary team spanning clinical development, biostatistics, regulatory affairs, clinical operations, and scientific leadership conducted a comprehensive review of the data to better understand the factors influencing treatment outcome.

Rather than accepting the study outcomes as a setback, the team used the insights gained to refine and more clearly define the patient population most likely to benefit from the investigational product. This process required close collaboration across functions, continued engagement with clinical investigators, and regulatory alignment to ensure the study appropriately reflected the benefits of the investigational product while incorporating key learnings from the earlier trial.

The result was a successful late-stage development effort that demonstrated the value of evidence-based adaptation. By applying insights from the earlier study to further refine the study population, the team was able to redesign the pivotal trial around the patients most likely to benefit from the investigational product, execute a rigorous global Phase III study, and generate meaningful clinical evidence supporting the potential of the therapy in the appropriately defined patient population.

That process reinforced an important lesson: unsuccessful trials rarely tell a single story. When examined with scientific rigor and an open mind, they can reveal critical insights that inform better development strategies, stronger trial designs, and a clearer path forward.

In this case, the analysis identified a meaningful treatment effect within a clearly defined high-risk patient population at increased risk of developing surgical site infections, indicating that the therapeutic approach retained significant promise while also highlighting the importance of refining the population studied. Translating those insights into a redesigned pivotal trial demanded scientific discipline, regulatory engagement and confidence in the data. It also required clinical research professionals to re-engage study sites and clinical investigators to restore momentum following clinical trial that had fallen short of expectations.

The redesigned study ultimately enrolled approximately 1000 patients across nearly 60 international sites and became one of the largest surgical infection prevention studies conducted in more than a decade. By refining the patient population and maintaining rigorous scientific standards, the trial successfully met its primary endpoint and key secondary endpoints, demonstrating a statistically significant 60% reduction in surgical site infections compared with standard care.

Perhaps the most important lesson, however, is that successful clinical development is rarely a linear process. Innovation often requires resilience as much as scientific excellence. The willingness to learn from failure, challenge assumptions, and redesign trial design based on robust evidence can transform an apparent setback into a pivotal milestone.

As therapeutic innovation continues to accelerate, the role of clinical research professionals will continue to evolve from operational experts to strategic leaders capable of navigating scientific uncertainty while maintaining the highest standards of patient safety and data integrity. Ultimately, the greatest measure of success is not simply advancing a product through development but ensuring that every decision throughout the clinical journey contributes to meaningful improvements in patient care.

About the author

Eyal Shoshani is vice president of clinical affairs at PolyPid and a seasoned clinical operations leader with 20 years’ experience spanning drug, biologic, cell therapy, and medical device development. He has directed multinational trials from Phase I-IV under FDA, EMA, and IMOH regulations, including a successful FDA BLA approval. Previously, he held senior clinical roles at Gamida Cell, Minovia Therapeutics, Pluristem Therapeutics, and Dexcel Pharma, after starting his career at IQVIA.

With expertise in clinical operations, project management, and regulatory compliance, Eyal has successfully led global development programs from early-stage trials through approval. He holds a BSc, MBA, and a certification in Orphan Drugs Clinical Trials.